Despite referring to the unexpected reversal of the FDA's position on MSB - the authors are believing it and using it as a basis for a near term CYP uplift.
Why -because MSB suggests it is so.
Classic nearology crap.
If MSB doesn't get its BLA what then for CYP? Not handled in the report.
Will MSB actually be able to get a BLA - what evaluation of the evidence provided by MSB is done - also not handled in the report.
Reports value -- zero in my opinion.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $38.41M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.5¢ | $21.40K | 127.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 425750 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 90178 | 3 |
View Market Depth
| Last trade - 14.06pm 13/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |